Abstract Number: 2528 • 2018 ACR/ARHP Annual Meeting
A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder associated with chronic inflammation and commonly treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. Repository corticotropin injection…Abstract Number: 2529 • 2018 ACR/ARHP Annual Meeting
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
Background/Purpose: Sarilumab showed efficacy in RA and superiority to placebo and adalimumab in Phase 3 trials. This post hoc analysis investigated LFT levels in three…Abstract Number: 2530 • 2018 ACR/ARHP Annual Meeting
Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Background/Purpose: Biosimilar agents have changed the clinical landscape in rheumatology, gastroenterology, and dermatology. We sought to measure clinicians’ competence and knowledge of biosimilars and to…Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…Abstract Number: 2533 • 2018 ACR/ARHP Annual Meeting
Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel.In 2016, the Rheumatology Department at Blackpool…Abstract Number: 2534 • 2018 ACR/ARHP Annual Meeting
Impact of Block Switch to Biosimilar Etanercept in Practice, Accross Different Rheumatic Diseases
Background/Purpose: Biosimilars of biotechnological agents represent an important opportunity to increase accessibility to these medications. Clinicians still maintain reservations regarding the similarity of their efficacy…Abstract Number: 2535 • 2018 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CKD-506, a Novel, Histone Deacetylase 6 (HDAC6) Inhibitor, in Healthy Volunteers
Background/Purpose: HDAC6 is a pleiotropic enzyme which removes of acetyl groups from non-histone proteins. HDAC6 inhibition represses inflammatory responses such as cytokines, chemokines and cell…Abstract Number: 2536 • 2018 ACR/ARHP Annual Meeting
Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy
Background/Purpose: RA is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Modulating innate neuro-immune reflex pathways by stimulation of the vagus…Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…Abstract Number: 2538 • 2018 ACR/ARHP Annual Meeting
Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg…Abstract Number: 2539 • 2018 ACR/ARHP Annual Meeting
SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
Background/Purpose: In the United Kingdom (UK) since 2016, etanercept biosimilars (SB4) are since 2016 a first-line treatment option for the management of severe rheumatoid arthritis…Abstract Number: 2540 • 2018 ACR/ARHP Annual Meeting
Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Background/Purpose: Good evidence suggests a relationship between rheumatoid arthritis (RA) and periodontitis. We aimed to investigate if a good oral hygiene could improve activity of…Abstract Number: 2541 • 2018 ACR/ARHP Annual Meeting
Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor, demonstrated efficacy through 12 and 24 weeks (wks) in phase 3 trials of patients (pts) with active rheumatoid…Abstract Number: 2542 • 2018 ACR/ARHP Annual Meeting
Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies
Background/Purpose: Upadacitinib is an oral, selective inhibitor of Janus kinase 1 (JAK1) which is currently being evaluated for the treatment of several autoimmune disorders, including…
ACR Meeting Abstracts